These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38358343)

  • 41. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
    He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
    World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease.
    Liu J; Ma KL; Zhang Y; Wu Y; Hu ZB; Lv LL; Tang RN; Liu H; Ruan XZ; Liu BC
    Int J Biochem Cell Biol; 2015 Apr; 61():8-19. PubMed ID: 25622557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
    Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
    Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
    Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
    Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
    Lebeau P; Al-Hashimi A; Sood S; Lhoták Š; Yu P; Gyulay G; Paré G; Chen SR; Trigatti B; Prat A; Seidah NG; Austin RC
    J Biol Chem; 2017 Jan; 292(4):1510-1523. PubMed ID: 27909053
    [TBL] [Abstract][Full Text] [Related]  

  • 49. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
    Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.
    Hyrina A; Olmstead AD; Steven P; Krajden M; Tam E; Jean F
    EBioMedicine; 2017 Sep; 23():68-78. PubMed ID: 28864162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
    Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
    J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
    Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk W; Le May C; Cariou B
    Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Research progress in the correlation between SREBP/PCSK9 pathway and lipid metabolism disorders induced by antipsychotics.
    Ma J; Zheng Y; Sun F; Fan Y; Fan Y; Su X; Wang Z; Weng N; Li R
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 48(10):1529-1538. PubMed ID: 38432882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exogenous hydrogen sulfide alleviates hepatic endoplasmic reticulum stress via SIRT1/FoxO1/PCSK9 pathway in NAFLD.
    Cui X; Yao M; Feng Y; Li C; Li Y; Guo D; He S
    FASEB J; 2023 Aug; 37(8):e23027. PubMed ID: 37410029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
    Di Filippo M; Vokaer B; Seidah NG
    J Clin Lipidol; 2017; 11(4):1101-1105. PubMed ID: 28711549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.